Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ingredient in its weight-loss drugs Ozempic and Wegovy, to lower heart risks.

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...

Novo Nordisk shares have dropped ~50% since June 2024 due to poor trial results and other negative catalysts. See why I rate ...

Novo Nordisk’s (NVO) stock has dropped by 25% in March (on the Copenhagen exchange) to put it on track for its biggest ...

Investing.com -- Barclays has lowered its first-quarter 2025 estimates for Novo Nordisk (CSE: NOVOb) (NYSE: NVO) ahead of its ...

While gastrointestinal issues are the most common side effects, a recent study by the University of British Columbia linked ...

Danish drugmaker Novo Nordisk is looking at an early launch of its blockbuster weight-loss drug Wegovy in India to better ...

The immense demand for Ozempic and Wegovy has also strained ... Therefore, I think buying Novo Nordisk stock at these prices will prove wise in hindsight.